Patents Assigned to Bayer Aktiengesellschaft
  • Publication number: 20200139393
    Abstract: The invention relates to a modular system for weed control for a rail vehicle. The modular system has a control module including a control unit and a control module. The control unit is configured to generate a first set of control signals for controlling valves and mixers in an herbicide and mixing module configured to mix an herbicide mixture and to generate a second set of control signals for controlling valves of a nozzle assembly. The herbicide and mixing module has a plurality of containers for receiving different herbicides. The nozzle assembly has a first set of nozzles for spraying herbicides, and the control module, the herbicide and mixing module, and the nozzle assembly can each be individually fixed to a carrier element in a reversible manner.
    Type: Application
    Filed: April 23, 2018
    Publication date: May 7, 2020
    Applicant: Bayer Aktiengesellschaft
    Inventors: Hinnerk BASSFELD, Thomas ARIANS, Nils KEILHOLZ
  • Publication number: 20200131169
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 1, 2019
    Publication date: April 30, 2020
    Applicant: Bayer Aktiengesellschaft
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
  • Publication number: 20200123174
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: March 22, 2018
    Publication date: April 23, 2020
    Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
  • Publication number: 20200123129
    Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 23, 2020
    Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: Stefan Nikolaus GRADL, Duy NGUYEN, Knut EIS, Judith GÜNTHER, Timo STELLFELD, Andreas JANZER, Sven CHRISTIAN, Thomas MÜLLER, Sherif El SHEIKH, Han Jie ZHOU, Changjia ZHAO, David B. SYKES, Steven James FERRARA, Kery LIU, Michael KRÖBER, Claudia MERZ, Michael NIEHUES, Martina SCHÄFER, Katja ZIMMERMANN, Carl Friedrich NISING
  • Publication number: 20200109155
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 9, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
  • Patent number: 10611779
    Abstract: The invention relates to novel compounds of the formula (I) in which Q, Aa, Ab, Ac, Ad, R1 and n have the definitions given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: April 7, 2020
    Assignees: Bayer CropScience Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ruediger Fischer, Dominik Hager, Laura Hoffmeister, Nina Kausch-Busies, Marc Mosrin, David Wilcke, Matthieu Willot, Kerstin Ilg, Ulrich Goergens, Andreas Turberg
  • Publication number: 20200095741
    Abstract: The invention relates to a modular system for weed control for a rail vehicle. The modular system has a control unit for producing control signals for controlling valves and mixers in a separate herbicide and mixing module and for producing a second set of control signals for controlling valves of a nozzle rod. The herbicide and mixing module has a container for holding different herbicides and electrical connection elements for connections to the control unit. Furthermore, a nozzle rod is present, which is fitted with a nozzle set, in order to spray herbicides of the herbicide and mixing module. In addition, a camera module is present, which produces a weed signal in response to the detection of a weed, in order to control the spraying of the herbicides. The camera module is at such a distance from the nozzle rod that, despite high speed, there is sufficient time to provide the herbicide at the nozzles.
    Type: Application
    Filed: April 24, 2018
    Publication date: March 26, 2020
    Applicant: Bayer Aktiengesellschaft
    Inventors: Hinnerk BAßFELD, Thomas ARIANS, Nils KEILHOLZ
  • Publication number: 20200077648
    Abstract: The present invention relates to compounds of the formula (I), in particular to phenoxyphenylamidines of the formula (I), to a process for their preparation, to the use of phenoxyphenylamidines of the formula (I) according to the invention for controlling unwanted microorganisms, in particular phytopathogenic fungi and also to a composition for this purpose, comprising the phenoxyphenylamidines of the formula (I) according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms, in particular phytopathogenic fungi, characterized in that the compounds of the formula (I) are applied to the microorganisms, in particular to the phytopathogenic fungi and/or in their habitat.
    Type: Application
    Filed: December 13, 2017
    Publication date: March 12, 2020
    Applicants: Bayer CropScience Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Cyril MONTAGNE, Stefan HILLEBRAND, Mazen ES-SAYED, Andreas GÖRTZ, Ulrike WACHENDORFF-NEUMANN, Thomas SEITZ, Jörg GREUL, Sergii PAZENOK, Klaus KUNZ
  • Publication number: 20200063212
    Abstract: The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyra-zol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject.
    Type: Application
    Filed: February 22, 2018
    Publication date: February 27, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Antje Margret WENGNER, Gerhard SIEMEISTER, Bernard HÄNDLER, Sven GOLFIER, Andreas SCHLICKER, Li LIU
  • Publication number: 20200062741
    Abstract: The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.
    Type: Application
    Filed: February 1, 2018
    Publication date: February 27, 2020
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: TIMOTHY A. LEWIS, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, MANUEL ELLERMANN, PHILIP LIENAU, KNUT EIS, ANTJE MARGRET WENGNER, CHARLOTTE CHRISTINE KOPITZ, MARTIN LANGE
  • Publication number: 20200055842
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 9, 2017
    Publication date: February 20, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
  • Publication number: 20200030270
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 30, 2020
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Kusel
  • Publication number: 20200027540
    Abstract: The invention relates to the technical field of supporting patients in the repeated taking of drugs within the context of a therapeutic treatment. The invention relates to a method, to a system, and to a computer program product that monitor the taking of drugs by a patient and inform the patient or a doctor or another person if a drug portion should not be taken in order to thus optimize the effectiveness of the treatment or reduce risks.
    Type: Application
    Filed: March 16, 2018
    Publication date: January 23, 2020
    Applicant: Bayer Aktiengesellschaft
    Inventors: Hubert TRÜBEL, Philip Patrick BÖHME, Martin VAN EICKELS, Wilfried DINH, Frank KRAMER, Carlos CASTELLON
  • Patent number: 10526314
    Abstract: The present invention relates to novel 5-(hydroxyalkyl)-1-heteroaryl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 7, 2020
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marie-Pierre Collin-Kröpelin, Peter Kolkhof, Thomas Neubauer, Chantal Fürstner, Elisabeth Pook, Matthias Beat Wittwer, Carsten Schmeck, Pierre Wasnaire, Hanna Tinel, Heiko Schirmer
  • Publication number: 20200000939
    Abstract: The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 2, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Simone Romoli, Tobias Bauch, Karoline Dröbner
  • Patent number: 10519154
    Abstract: The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: December 31, 2019
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Henrik Teller, Melissa Boultadakis Arapinis, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximillian Andreas Kullmann, Klaus Münter, Thomas Mondritzki, Tobias Marquardt
  • Publication number: 20190388425
    Abstract: The present invention relates to substituted imidazopyridinpyrimidine compounds of general formula (I) which inhibit MKNK1 and MKNK2 kinase (also known as MAP Kinase interacting Kinase, Mnk1 and Mnk2), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 26, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ
  • Patent number: 10514375
    Abstract: The invention relates to a device (1) and a method for determining the action of active ingredients on nematodes and other organisms in aqueous tests.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: December 24, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Franco Fois, Michael Harnau, Klaus Ochmann
  • Publication number: 20190375747
    Abstract: The present invention provides triazolone compounds compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 25, 2017
    Publication date: December 12, 2019
    Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: Stefan Nikolaus GRADL, Duy NGUYEN, Knut EIS, Judith GÜNTHER, Timo STELLFELD, Andreas JANZER, Sven CHRISTIAN, Thomas MUELLER, Sherif El SHEIKH, Han Jie ZHOU, Changjia ZHAO, David B. SYKES, Steven James FERRARA, Kery LIU, Simon Anthony HERBERT, Claudia MERZ, Michael NIEHUES, Carl Friedrich NISING, Martina SCHÄFER, Katja ZIMMERMANN, Jörg KNÄBLEIN, Kai THEDE, Thomas FAUPEL
  • Publication number: 20190350910
    Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (A) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 15, 2018
    Publication date: November 21, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Rolf BOHLMANN, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ, Olaf PANKNIN